Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 11 December 1981:
Vol. 214. no. 4526, pp. 1239 - 1241
DOI: 10.1126/science.6795720
Prev | Table of Contents | Next

Articles

Science, Vol 214, Issue 4526, 1239-1241
Copyright © 1981 by American Association for the Advancement of Science

articles

Type III hyperlipoproteinemia associated with apolipoprotein E deficiency

G Ghiselli, EJ Schaefer, P Gascon, and HB Breser Jr

Subjects with type III hyperlipoproteinemia develop premature atherosclerosis and have hyperlipidemia due to an increase in cholesterol-rich very low density lipoproteins (VLDL) of abnormal electrophoretic mobility. Apolipoprotein E is a major protein constituent of VLDL and appears to be important for the hepatic uptake of triglyceride-rich lipoproteins. A new kindred of patients with type III hyperlipoproteinemia is described in which no plasma apolipoprotein E could be detected, consistent with the concept that type III hyperlipoproteinemia may be due to an absence or striking deficiency of apolipoprotein E.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Abnormal in vivo metabolism of apoB-containing lipoproteins in human apoE deficiency.
K. Ikewaki, W. Cain, F. Thomas, R. Shamburek, L. A. Zech, D. Usher, H. B. Brewer Jr., and D. J. Rader (2004)
J. Lipid Res. 45, 1302-1311
   Abstract »    Full Text »    PDF »
Mesangial expansion associated with glomerular endothelial cell activation and macrophage recruitment is developing in hyperlipidaemic apoE null mice.
P. Bruneval, J. Bariety, M.-F. Belair, C. Mandet, D. Heudes, and A. Nicoletti (2002)
Nephrol. Dial. Transplant. 17, 2099-2107
   Abstract »    Full Text »    PDF »
Atherosclerosis in C3H/HeJ Mice Reconstituted With Apolipoprotein E-Null Bone Marrow.
W. Shi, X. Wang, K. Tangchitpiyanond, J. Wong, Y. Shi, and A. J. Lusis (2002)
Arterioscler. Thromb. Vasc. Biol. 22, 650-655
   Abstract »    Full Text »    PDF »
Pathophysiology of apolipoprotein E deficiency in mice: relevance to apo E-related disorders in humans.
M. H. MOGHADASIAN, B. M. McMANUS, L. B. NGUYEN, S. SHEFER, M. NADJI, D. V. GODIN, T. J. GREEN, J. HILL, Y. YANG, C. H. SCUDAMORE, et al. (2001)
FASEB J 15, 2623-2630
   Abstract »    Full Text »    PDF »
VLDL, Apolipoproteins B, CIII, and E, and Risk of Recurrent Coronary Events in the Cholesterol and Recurrent Events (CARE) Trial.
F. M. Sacks, P. Alaupovic, L. A. Moye, T. G. Cole, B. Sussex, M. J. Stampfer, M. A. Pfeffer, and E. Braunwald (2000)
Circulation 102, 1886-1892
   Abstract »    Full Text »    PDF »
Effect of Macrophage-Derived Apolipoprotein E on Established Atherosclerosis in Apolipoprotein E-Deficient Mice.
W. Shi, X. Wang, N. J. Wang, W. H. McBride, and A. J. Lusis (2000)
Arterioscler. Thromb. Vasc. Biol. 20, 2261-2266
   Abstract »    Full Text »    PDF »
Effect of Macrophage-Derived Mouse ApoE, Human ApoE3-Leiden, and Human ApoE2 (Arg158->Cys) on Cholesterol Levels and Atherosclerosis in ApoE-Deficient Mice.
M. Van Eck, N. Herijgers, K. W. Van Dijk, L. M. Havekes, M. H. Hofker, P. H. E. Groot, and T. J. C. Van Berkel (2000)
Arterioscler. Thromb. Vasc. Biol. 20, 119-127
   Abstract »    Full Text »    PDF »
Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia): questions, quandaries, and paradoxes.
R. W. Mahley, Y. Huang, and S. C. Rall , Jr. (1999)
J. Lipid Res. 40, 1933-1949
   Abstract »    Full Text »
Low-Cholesterol and High-Fat Diets Reduce Atherosclerotic Lesion Development in ApoE-Knockout Mice.
L. Calleja, M. A. Paris, A. Paul, E. Vilella, J. Joven, A. Jimenez, G. Beltran, M. Uceda, N. Maeda, and J. Osada (1999)
Arterioscler. Thromb. Vasc. Biol. 19, 2368-2375
   Abstract »    Full Text »    PDF »
Determination of the lower threshold of apolipoprotein E resulting in remnant lipoprotein clearance.
A. H. Hasty, M. F. Linton, L. L. Swift, and S. Fazio (1999)
J. Lipid Res. 40, 1529-1538
   Abstract »    Full Text »
Apolipoprotein E Deficiency Worsens Outcome From Global Cerebral Ischemia in the Mouse • Editorial Comment.
H. Sheng, D. T. Laskowitz, G. B. Mackensen, M. Kudo, R. D. Pearlstein, D. S. Warner, and C. Iadecola (1999)
Stroke 30, 1118-1124
   Abstract »    Full Text »    PDF »
Agonist-specific impairment of coronary vascular function in genetically altered, hyperlipidemic mice.
K. G. Lamping, D. W. Nuno, D. A. Chappell, and F. M. Faraci (1999)
Am J Physiol Regulatory Integrative Comp Physiol 276, R1023-R1029
   Abstract »    Full Text »    PDF »
Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E.
R. W. Mahley and Z.-S. Ji (1999)
J. Lipid Res. 40, 1-16
   Abstract »    Full Text »
Lamellar lipoproteins uniquely contribute to hyperlipidemia in mice doubly deficient in apolipoprotein E and hepatic lipase.
N. Bergeron, L. Kotite, M. Verges, P. Blanche, R. L. Hamilton, R. M. Krauss, A. Bensadoun, and R. J. Havel (1998)
PNAS 95, 15647-15652
   Abstract »    Full Text »    PDF »
Resistance of chylomicron and VLDL remnants to post-heparin lipolysis in ApoE-deficient mice: the role of apoE in lipoprotein lipase-mediated lipolysis in vivo and in vitro.
E. Zsigmond, Y. Fuke, L. Li, K. Kobayashi, and L. Chan (1998)
J. Lipid Res. 39, 1852-1861
   Abstract »    Full Text »
Low-dose expression of a human apolipoprotein E transgene in macrophages restores cholesterol efflux capacity of apolipoprotein E-deficient mouse plasma.
Y. Zhu, S. Bellosta, C. Langer, F. Bernini, R. E. Pitas, R. W. Mahley, G. Assmann, and A. von Eckardstein (1998)
PNAS 95, 7585-7590
   Abstract »    Full Text »    PDF »
Bone Marrow Transplantation in Apolipoprotein E–Deficient Mice : Effect of ApoE Gene Dosage on Serum Lipid Concentrations, (ß)VLDL Catabolism, and Atherosclerosis.
M. Van Eck, N. Herijgers, J. Yates, N. J. Pearce, P. M. Hoogerbrugge, P. H. E. Groot, and T. J. C. Van Berkel (1997)
Arterioscler. Thromb. Vasc. Biol. 17, 3117-3126
   Abstract »    Full Text »
Preliminary Report of a Genetic Basis for Cognitive Decline After Cardiac Operations.
B. E. Tardiff, M. F. Newman, A. M. Saunders, W. J. Strittmatter, J. A. Blumenthal, W. D. White, N. D. Croughwell, R. D. Davis Jr, A. D. Roses, and J. G. Reves (1997)
Ann. Thorac. Surg. 64, 715-720
   Abstract »    Full Text »
Increased atherosclerosis in mice reconstituted with apolipoprotein E null macrophages.
S. Fazio, V. R. Babaev, A. B. Murray, A. H. Hasty, K. J. Carter, L. A. Gleaves, J. B. Atkinson, and M. F. Linton (1997)
PNAS 94, 4647-4652
   Abstract »    Full Text »    PDF »
Uptake by J774 Macrophages of Very-Low-Density Lipoproteins Isolated From ApoE-Deficient Mice Is Mediated by a Distinct Receptor and Stimulated by Lipoprotein Lipase.
W. L. Hendriks, F. van der Sman-de Beer, B. J.M. van Vlijmen, L. C. van Vark, M. H. Hofker, and L. M. Havekes (1997)
Arterioscler. Thromb. Vasc. Biol. 17, 498-504
   Abstract »    Full Text »
In the Absence of Endogenous Mouse Apolipoprotein E, Apolipoprotein E*2(Arg-158 right-arrow Cys) Transgenic Mice Develop More Severe Hyperlipoproteinemia than Apolipoprotein E*3-Leiden Transgenic Mice.
B. J.M. van Vlijmen, K. W. van Dijk, H. B. van't Hof, P. J.J. van Gorp, A. van der Zee, H. van der Boom, M. L. Breuer, M. H. Hofker, and L. M. Havekes (1996)
J. Biol. Chem. 271, 30595-30602
   Abstract »    Full Text »    PDF »
Prevention of atherosclerosis in apolipoprotein E-deficient mice by bone marrow transplantation.
M. Linton, J. Atkinson, and S Fazio (1995)
Science 267, 1034-1037
   Abstract »    PDF »
Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E.
S. Zhang, R. Reddick, J. Piedrahita, and N Maeda (1992)
Science 258, 468-471
   Abstract »    PDF »
Apolipoprotein E: cholesterol transport protein with expanding role in cell biology.
R. Mahley (1988)
Science 240, 622-630
   Abstract »    PDF »
Type III Hyperlipoproteinemia: Diagnosis, Molecular Defects, Pathology, and Treatment.
H. B. BREWER Jr., L. A. ZECH, R. E. GREGG, D. SCHWARTZ, and E. J. SCHAEFER (1983)
Ann Intern Med 98, 623-640
   Abstract »    PDF »
Domains of Apolipoprotein E Contributing to Triglyceride and Cholesterol Homeostasis in Vivo. CARBOXYL-TERMINAL REGION 203-299 PROMOTES HEPATIC VERY LOW DENSITY LIPOPROTEIN-TRIGLYCERIDE SECRETION.
K. E. Kypreos, K. W. van Dijk, A. van der Zee, L. M. Havekes, and V. I. Zannis (2001)
J. Biol. Chem. 276, 19778-19786
   Abstract »    Full Text »    PDF »
Atherosclerosis in C3H/HeJ Mice Reconstituted With Apolipoprotein E-Null Bone Marrow.
W. Shi, X. Wang, K. Tangchitpiyanond, J. Wong, Y. Shi, and A. J. Lusis (2002)
Arterioscler. Thromb. Vasc. Biol. 22, 650-655
   Abstract »    Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)